These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
140 related items for PubMed ID: 8788547
1. Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma. Montemurro P, Conese M, Altomare DF, Memeo V, Colucci M, Semeraro N. Int J Clin Lab Res; 1995; 25(4):195-200. PubMed ID: 8788547 [Abstract] [Full Text] [Related]
2. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer. Ho CH, Chao Y, Lee SD, Chau WK, Wu CW, Liu SM. Thromb Res; 1998 Jul 01; 91(1):23-7. PubMed ID: 9700849 [Abstract] [Full Text] [Related]
4. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K, van de Velde CJ, Verheijen JH, Lamers CB, Verspaget HW. Br J Cancer; 1997 Jul 01; 75(12):1793-801. PubMed ID: 9192984 [Abstract] [Full Text] [Related]
8. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, Takada A, Nakamura S. Cancer; 1999 Dec 15; 86(12):2602-11. PubMed ID: 10594855 [Abstract] [Full Text] [Related]
12. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis. Robbie LA, Dummer S, Booth NA, Adey GD, Bennett B. Br J Haematol; 2000 May 15; 109(2):342-8. PubMed ID: 10848822 [Abstract] [Full Text] [Related]
13. Hemostatic alterations in patients with benign and malignant colorectal disease during major abdominal surgery. Modrau II, Iversen LL, Thorlacius-Ussing OO. Thromb Res; 2001 Dec 01; 104(5):309-15. PubMed ID: 11738072 [Abstract] [Full Text] [Related]
14. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Sier CF, Vloedgraven HJ, Ganesh S, Griffioen G, Quax PH, Verheijen JH, Dooijewaard G, Welvaart K, van de Velde CJ, Lamers CB. Gastroenterology; 1994 Nov 01; 107(5):1449-56. PubMed ID: 7926508 [Abstract] [Full Text] [Related]
16. Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients. Halamkova J, Kiss I, Pavlovsky Z, Jarkovsky J, Tomasek J, Tucek S, Hanakova L, Moulis M, Cech Z, Zavrelova J, Penka M. Hepatogastroenterology; 2011 Nov 01; 58(112):1918-25. PubMed ID: 22234062 [Abstract] [Full Text] [Related]
19. Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms. Falkenberg M, Holmdahl L, Tjärnström J, Risberg B. Eur J Surg; 2001 Jan 01; 167(1):10-4. PubMed ID: 11213813 [Abstract] [Full Text] [Related]
20. Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta. Moniwa N. Pol J Pharmacol; 1996 Jan 01; 48(2):215-20. PubMed ID: 9112654 [Abstract] [Full Text] [Related] Page: [Next] [New Search]